• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫反应性丙二醛修饰的低密度脂蛋白在人血清中的分布

Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.

作者信息

Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M

机构信息

Department of Laboratory Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

出版信息

Biochim Biophys Acta. 1994 Nov 17;1215(1-2):121-5. doi: 10.1016/0005-2760(94)90100-7.

DOI:10.1016/0005-2760(94)90100-7
PMID:7947993
Abstract

We developed a sensitive enzyme-linked immunosorbent assay (ELISA) for detection of malondialdehyde-modified low-density lipoprotein (MDA-LDL) in human serum. A monoclonal antibody against MDA-LDL (ML25) used in our method recognized not only MDA-LDL but also other MDA-modified proteins. However, MDA-LDL was able to be detected specifically by using a combination of ML25 and an antibody specific for apolipoprotein B (apo B) (AB16), which was conjugated with beta-galactosidase. Using this method, measurable amounts of MDA-LDL were detected in the sera of 40 healthy individuals. MDA-LDL was observed to be mainly distributed in the human LDL fraction separated by density gradient ultracentrifugation, while in each lipoprotein subfraction the largest amount of MDA-LDL per protein was found at a subfraction between LDL and HDL. The particle size of LDL in this fraction was smaller than that of LDL in the main LDL fraction, as assessed by electrophoresis. In addition, LDL oxidized by Cu2+ was also detectable with this method. We conclude that our method is sensitive and specific for MDA-LDL and might be useful for investigating MDA-LDL in the human circulation.

摘要

我们开发了一种灵敏的酶联免疫吸附测定法(ELISA),用于检测人血清中的丙二醛修饰的低密度脂蛋白(MDA-LDL)。我们方法中使用的抗MDA-LDL单克隆抗体(ML25)不仅能识别MDA-LDL,还能识别其他MDA修饰的蛋白质。然而,通过将ML25与特异性针对载脂蛋白B(apo B)的抗体(AB16)结合使用,能够特异性检测MDA-LDL,该抗体与β-半乳糖苷酶偶联。使用这种方法,在40名健康个体的血清中检测到了可测量量的MDA-LDL。通过密度梯度超速离心分离的人LDL组分中观察到MDA-LDL主要分布在其中,而在每个脂蛋白亚组分中,每蛋白质中MDA-LDL含量最高的是在LDL和HDL之间的一个亚组分中。通过电泳评估,该组分中LDL的粒径小于主要LDL组分中LDL的粒径。此外,用这种方法也能检测到被Cu2+氧化的LDL。我们得出结论,我们的方法对MDA-LDL灵敏且特异,可能有助于研究人体循环中的MDA-LDL。

相似文献

1
Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.免疫反应性丙二醛修饰的低密度脂蛋白在人血清中的分布
Biochim Biophys Acta. 1994 Nov 17;1215(1-2):121-5. doi: 10.1016/0005-2760(94)90100-7.
2
[Determination of malondialdehyde-modified LDL(MDA-LDL) and its potential usefulness].丙二醛修饰低密度脂蛋白(MDA-LDL)的测定及其潜在用途
Rinsho Byori. 1997 Jan;45(1):47-54.
3
Gold nanoparticle-antibody conjugates for specific extraction and subsequent analysis by liquid chromatography-tandem mass spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for cardiovascular risk.用于特异性提取并随后通过液相色谱-串联质谱法分析丙二醛修饰的低密度脂蛋白的金纳米颗粒-抗体缀合物,丙二醛修饰的低密度脂蛋白作为心血管风险的生物标志物。
Anal Chim Acta. 2015 Feb 1;857:53-63. doi: 10.1016/j.aca.2014.12.024. Epub 2014 Dec 16.
4
Influence of fibrate treatment on malondialdehyde-modified LDL concentration.贝特类药物治疗对丙二醛修饰低密度脂蛋白浓度的影响。
Clin Chim Acta. 2004 Jan;339(1-2):97-103. doi: 10.1016/j.cccn.2003.09.005.
5
Immunogenicity of malondialdehyde-modified low density lipoproteins. Studies with monoclonal antibodies.丙二醛修饰的低密度脂蛋白的免疫原性。单克隆抗体研究。
Atherosclerosis. 1987 Jun;65(3):265-72. doi: 10.1016/0021-9150(87)90042-6.
6
Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.类风湿关节炎患者体内针对铜氧化低密度脂蛋白、丙二醛修饰低密度脂蛋白和心磷脂的自身抗体水平升高。
Rheumatology (Oxford). 2002 Sep;41(9):988-95. doi: 10.1093/rheumatology/41.9.988.
7
Generation and characterization of IgG monoclonal antibodies specific for malondialdehyde.丙二醛特异性IgG单克隆抗体的产生与鉴定
Hybrid Hybridomics. 2003 Aug;22(4):259-62. doi: 10.1089/153685903322328983.
8
Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.原发性高血压患者体内抗氧化修饰低密度脂蛋白自身抗体的存在:体内低密度脂蛋白氧化增强的生化特征。
J Hypertens. 1995 Jan;13(1):129-38.
9
Development of capture assays for different modifications of human low-density lipoprotein.针对人低密度脂蛋白不同修饰的捕获检测方法的开发。
Clin Diagn Lab Immunol. 2005 Jan;12(1):68-75. doi: 10.1128/CDLI.12.1.68-75.2005.
10
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.动脉粥样硬化疾病患者体内的丙二醛修饰低密度脂蛋白
J Clin Invest. 1995 Jun;95(6):2611-9. doi: 10.1172/JCI117963.

引用本文的文献

1
Cardioprotective effects of CoQ10 in pediatric patients with lysosomal storage disorders.辅酶Q10对溶酶体贮积症患儿的心脏保护作用。
Ital J Pediatr. 2025 May 28;51(1):163. doi: 10.1186/s13052-025-02008-5.
2
Effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study.非布司他对氧化应激标志物丙二醛修饰的低密度脂蛋白水平的影响:PRIZE 研究的亚分析。
Clin Cardiol. 2023 Jun;46(6):698-706. doi: 10.1002/clc.24014. Epub 2023 Mar 29.
3
Malondialdehyde-Modified Low-Density Lipoprotein as a Predictor of Major Adverse Limb Events after Endovascular Therapy in Patients with Lower Extremity Arterial Disease.
丙二醛修饰的低密度脂蛋白作为下肢动脉疾病患者血管内治疗后主要肢体不良事件的预测因子。
J Atheroscler Thromb. 2023 Nov 1;30(11):1612-1621. doi: 10.5551/jat.64091. Epub 2023 Mar 9.
4
Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk.致动脉粥样硬化脂蛋白与他汀类药物残余心血管疾病风险。
Int J Mol Sci. 2022 Nov 4;23(21):13499. doi: 10.3390/ijms232113499.
5
Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.鲁格列净和伏格列波糖对心力衰竭糖尿病患者高危血脂谱和炎症标志物的影响。
Sci Rep. 2022 Sep 14;12(1):15449. doi: 10.1038/s41598-022-19371-6.
6
Structure and Dynamics of Oxidized Lipoproteins In Vivo: Roles of High-Density Lipoprotein.体内氧化脂蛋白的结构与动力学:高密度脂蛋白的作用
Biomedicines. 2021 Jun 8;9(6):655. doi: 10.3390/biomedicines9060655.
7
Atorvastatin Reduces Circulating S100A12 Levels in Patients with Carotid Atherosclerotic Plaques - A Link with Plaque Inflammation.阿托伐他汀可降低颈动脉粥样硬化斑块患者的循环 S100A12 水平——与斑块炎症相关。
J Atheroscler Thromb. 2022 May 1;29(5):775-784. doi: 10.5551/jat.61630. Epub 2021 May 1.
8
Effects of PCSK9 Inhibitor on Favorable Limb Outcomes in Patients with Chronic Limb-Threatening Ischemia.PCSK9 抑制剂对慢性肢体威胁性缺血患者有利肢体结局的影响。
J Atheroscler Thromb. 2021 Jul 1;28(7):754-765. doi: 10.5551/jat.57653. Epub 2020 Sep 25.
9
Relationships of Fatty Acids, Delta-5 Desaturase Activity, and Lipid Profiles in Men with Acute Coronary Syndrome.急性冠状动脉综合征男性患者脂肪酸、Δ5 去饱和酶活性与血脂谱的关系。
J Atheroscler Thromb. 2020 Nov 1;27(11):1216-1229. doi: 10.5551/jat.55780. Epub 2020 Jun 27.
10
Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL.在急性心肌梗死患者中增加的循环氧化 LDL 伴随着大量修饰的 HDL。
J Lipid Res. 2020 Jun;61(6):816-829. doi: 10.1194/jlr.RA119000312. Epub 2020 Apr 14.